Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,655 | -6,249 | -28,452 | -22,264 | -15,680 |
| Depreciation Amortization | -1,393 | -777 | -255 | N/A | N/A |
| Accounts receivable | -4,124 | -1,294 | 405 | N/A | 525 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -1,629 |
| Other Working Capital | -1,284 | -1,939 | 60 | -535 | -1,104 |
| Other Operating Activity | 5,993 | 2,278 | 2,901 | 2,595 | 2,836 |
| Operating Cash Flow | $-16,463 | $-7,981 | $-25,341 | $-20,204 | $-15,052 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 15,451 | -15,169 | -62,354 | N/A | N/A |
| Net Acquisitions | N/A | N/A | 5,000 | 5,000 | 5,000 |
| Sale Of Investment | N/A | 11,600 | N/A | N/A | N/A |
| Investing Cash Flow | $15,451 | $-3,569 | $-57,354 | $5,000 | $5,000 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 82,821 | 156 | 156 |
| Other Financing Activity | -7 | -5 | -427 | -425 | -378 |
| Financing Cash Flow | $-7 | $-5 | $82,394 | $-269 | $-222 |
| Beginning Cash Position | 30,674 | 30,674 | 30,975 | 30,975 | 30,975 |
| End Cash Position | 29,655 | 19,119 | 30,674 | 15,502 | 20,701 |
| Net Cash Flow | $-1,019 | $-11,555 | $-301 | $-15,473 | $-10,274 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,463 | -7,981 | -25,341 | -20,204 | -15,052 |
| Free Cash Flow | -16,463 | -7,981 | -25,341 | -20,204 | -15,052 |